Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.
This biological assignment comparative study evaluated autologous stem cell transplantation (auto-SCT) versus matched sibling donor transplant (MSD-SCT) in intermediate-risk AML patients achieving MRD-negative status in first complete remission. Auto-SCT demonstrated non-inferior disease-free survival and similar overall survival compared to MSD-SCT, suggesting it is a viable and potentially preferable first-line consolidation option for MRD-negative IR-AML patients.
This biological assignment comparative study evaluated autologous stem cell transplantation (auto-SCT) versus matched sibling donor transplant (MSD-SCT) in intermediate-risk AML patients achieving MRD-negative status in first complete remission. Auto-SCT demonstrated non-inferior disease-free survival and similar overall survival compared to MSD-SCT, suggesting it is a viable and potentially preferable first-line consolidation option for MRD-negative IR-AML patients.
What the study was
- Study design
- Retrospective study
- Sample size
- 708
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Experimental hematology & oncology
Why it surfaced
Relevant Hematologic malignancies study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.